Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO and CLEVELAND, Ohio, November 22, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Juventas Therapeutics (President & CEO: Rahul Aras,...
TOKYO and NORTHBROOK, Ill., November 20, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced the launch of the Astellas Global Health...
TOKYO – November 19, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced it will present new data in Acute Myeloid Leukemia (AML)...
TOKYO, November 5, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the company’s mid-to-long term greenhouse gas (GHG)...
Read more about Science Based Targets Initiative Approves Astellas’ Greenhouse Gas Reduction Plan
TOKYO, October 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that construction and renovation of new facilities for the...
Follow us
